Indivior Pharmaceuticals, Inc. INDV Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.29B+10.2% | $1.24B+4.3% | $1.18B+1.5% | $1.17B+3.9% | $1.17B+6.1% | ||
| $242M+2.1% | $246M+6.5% | $227M+0.2% | $210M+2.9% | $237M+40.7% | ||
| $1.05B+12.3% | $994M+3.8% | $954M+1.8% | $964M+4.2% | $934M-0.1% | ||
| 81.3%+1.5pp | 80.2%-0.4pp | 80.8%+0.3pp | 82.1%+0.2pp | 79.8%-5.0pp | ||
| $91M-9.9% | $97M-9.3% | $107M+1.9% | $96M-14.3% | $101M-12.2% | ||
| $626M+4.0% | $635M+3.8% | $621M+7.4% | $608M+5.3% | $602M+6.2% | ||
| —— | —— | —— | —— | $905M-7.2% | ||
| $333M+1,048% | $262M+589% | $227M+593% | $219M+284% | $29M+174% | ||
| 25.8%+23.3pp | 21.1%+17.9pp | 19.2%+23.2pp | 18.7%+29.2pp | 2.5%+6.0pp | ||
| $40M-11.1% | $45M+7.1% | $52M+37.7% | $51M+43.7% | $45M+27.7% | ||
| $295M+4,817% | $239M+1,095% | $196M+461% | $189M+257% | $6M+117% | ||
| —— | —— | $67M+866% | $80M+472% | $13M+500% | ||
| $251M+3,686% | $209M+2,886% | $128M+381% | $108M+209% | -$7M+79.1% | ||
| 19.4%+20.0pp | 16.9%+16.3pp | 10.8%+14.7pp | 9.2%+18.0pp | -0.6%+2.4pp | ||
| $1.95+9,850% | $1.64+3,180% | $1.01+397% | $0.84+215% | -$0.02+91.7% | ||
| $342M+695% | $272M+404% | $240M+868% | $233M+323% | $43M+289% | ||
| 26.5%+22.8pp | 21.9%+17.4pp | 20.3%+23.0pp | 19.8%+29.1pp | 3.7%+5.7pp | ||
| $333M+1,048% | $262M+589% | $227M+593% | $219M+284% | $29M+174% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Indivior Pharmaceuticals, Inc. 's profit margins?
- Gross margin is 81.3% and operating margin is 25.8%, with a 19.4% net margin.
- Where does Indivior Pharmaceuticals, Inc. 's income statement data come from?
- Every line is extracted from Indivior Pharmaceuticals, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.